TRCV Growth and Predictability
Total recurring contract value (TRCV) reached $144.1M, up 8% year-over-year and 2% sequentially, marking the fifth consecutive quarter of sequential TRCV growth; 99% of revenue is recurring, reinforcing revenue visibility and predictability.
New Sales Acceleration
Full-year new sales increased 86% year-over-year following a sales team reorganization and refined coverage model that drove larger, more strategic relationships.
Improved Retention and Customer Satisfaction
Achieved the highest gross dollar retention rate in more than 7 years and a Net Promoter Score of 68; served 74% of the top 100 U.S. health systems, reflecting strong customer trust and engagement.
Rounding and Enablement Momentum
Rounding (workflow-driven enablement solution) saw TRCV nearly double in 2025, signaling strong adoption of enablement solutions and meaningful cross-sell opportunities across customers.
Strong Profitability and Margin Discipline
Full-year adjusted EBITDA was $40.2M with a 29% margin; Q4 adjusted EBITDA was $8.7M. Adjusted net income for the year was $20.7M with adjusted EPS of $0.93, and Q4 adjusted EPS was $0.16, demonstrating maintained profitability despite revenue headwinds.
Product Innovation and AI Integration
Investments in product innovation and AI (comment summarization, AI-enabled service recovery, AI-powered listening beta for Rounding) aimed at improving insight-to-action velocity and expanding addressable market.
Leadership and Strategic Hires
Senior hire of David Burik to lead strategic insights and governance strategy, strengthening expertise in governance, system transformation and accelerating growth of Market Insights and Governance Institute offerings.
Capital Allocation and Cash Returns
Demonstrated free cash flow durability and a disciplined approach to capital allocation: returned capital via a $0.12 per share quarterly dividend and signaled opportunistic share repurchases while retaining flexibility for strategic M&A.